Pan-cancer analysis revealed the correlation between SPP1 and clinical prognosis of multiple tumors
10.13699/j.cnki.1001-6821.2024.12.027
- VernacularTitle:泛癌分析揭示SPP1与多种肿瘤的临床预后相关性
- Author:
Jie CHEN
1
,
2
;
Mo ZHANG
;
Zhan-Yu MEN
;
Lin CHEN
;
Lu WANG
;
Xiao-Cong PANG
Author Information
1. 徐州医科大学药学院,江苏徐州 221009
2. 北京大学第一医院临床药理研究所,北京 100034
- Keywords:
secreted phosphoprotein 1;
prognosis;
DNA methylation;
gene mutation;
pan-cancer analysis
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(12):1827-1831
- CountryChina
- Language:Chinese
-
Abstract:
Objective This study utilized bioinformatics to investigate the role of secreted phosphoprotein 1(SPP1)in tumors and assess its differential expression and prognostic significance across human cancers.Method Cancer sample data was sourced from the Cancer Genome Atlas(TCGA)and Genotype-tissue Expression(GTEx)database.Analysis of gene expression differences in pan-cancer involving SPP1 utilized the CPTAC database,correlations between SPP1 and patient survival outcomes were assessed using GEPIA2,and alterations in gene mutations for SPP1 across 32 cancers were appraised via the CbioPortal tool.Results Across 32 tumor types,SPP1 mRNA disparity is observed in eight cancer types,decreasing only in clear cell renal carcinoma while increasing in other malignancies.Expression in tumor stage is specific;SPP1 mRNA negatively correlates with patient overall survival(OS)and disease-free survival(DFS);low methylation associated with SPP1 gene activity promotes oncogene activation,impacting tumor cell generation,apoptosis,and proliferation,thereby influencing cancer progression;SPP1 primarily exhibits missense mutations that correlate with poor prognoses in prostate and stomach cancer patients.Conclusion Through pan-cancer studies,SPP1's selective expression in human malignancies was validated and found to be strongly correlated with clinical prognosis.This suggests that SPP1 is a viable target for cancer prognostic precision.
